Related Experiment Video
Updated: Apr 25, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.6K
Informed shared decision making: An exploratory study in pharmacy
Rosemin Kassam1, Carlyn Volume-Smith2, Simon P Albon1
1Faculty of Pharmaceutical Sciences, University of British Columbia . Vancouver, BC ( Canada ).
Pharmacy Practice
|August 27, 2014
Summary
Pharmacists find the Informed Shared Decision Making (ISDM) framework relevant for building patient relationships. While developing partnerships is key, barriers to ISDM implementation in pharmacy practice exist.
Area of Science:
- Pharmacy Practice
- Health Sciences
- Patient Care
Background:
- Examining the feasibility of the physician-based Informed Shared Decision Making (ISDM) framework for pharmacy students.
- Focusing on developing competencies for effective therapeutic relationships with patients.
Purpose of the Study:
- Assess ISDM competency relevance and importance in pharmacy.
- Identify ease of practice, barriers, and ideal situations for ISDM in pharmacy.
- Evaluate ISDM for enhancing pharmacist-patient therapeutic relationships.
Main Methods:
- Interviewed 20 pharmacists across 4 practice settings.
- Utilized a standardized interview protocol to gather data.
- Explored perceptions of ISDM framework applicability and implementation.
Main Results:
- Pharmacists deemed most physician-based ISDM competencies relevant, with "Develop a partnership with the patient" rated highest.
- No single competency was deemed difficult, but barriers to ISDM implementation were identified.
- Patients with chronic conditions were considered ideal candidates for ISDM.
Conclusions:
- The ISDM model offers a potential framework for pharmacists to foster therapeutic relationships.
- Obstacles to the successful implementation of ISDM in pharmacy practice were recognized.
- Further exploration of ISDM in pharmacy is warranted to overcome identified challenges.
More Related Videos
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
96
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
96
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
241
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
241
01:12Analysis of Population Pharmacokinetic Data
992
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
992
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
01:26Drug Administration and Therapy Phases: Overview
1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
535
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
535